Skip to main content
. 2023 Jan 18;14:157. doi: 10.1038/s41467-022-32936-3

Table 2.

Lead variants for 27 significant association loci in the genome-wide association study meta-analysis of otosclerosis

Rsid Chr Position Effect allele Non-effect allele EAF Nearest Gene Consequence Meta-analysis OR (95% CI) P-value FinnGen OR (95% CI) UKBB OR (95% CI) EstBB OR (95% CI) Q p-value I2
rs77249084 8 116560300 G A 0.3 EIF3H Regulatory region 1.31 (1.24–1.38) 1.78E–23 1.44 (1.33–1.56) 1.21 (1.09–1.34) 1.22 (1.1–1.34) 0.0074 0.8
rs11868207 17 68679579 C T 0.23 FAM20A (LINC01482) Intergenic (Intronic) 1.34 (1.26–1.42) 1.25E–22 1.46 (1.33–1.6) 1.29 (1.16–1.43) 1.24 (1.11–1.38) 0.056 0.65
rs12270054 11 65555077 T C 0.22 LTBP3 Intronic 0.75 (0.71–0.8) 4.29E–20 0.68 (0.61–0.74) 0.76 (0.69–0.85) 0.86 (0.77–0.97) 0.0074 0.8
rs10592836 14 103471816 C CAAT 0.34 MARK3 Intronic 1.25 (1.19−1.32) 2.79E–18 1.35 (1.25–1.46) 1.2 (1.09–1.32) 1.16 (1.06–1.28) 0.032 0.71
rs71900142 10 30775253 G GCTTCTGGCTTAAGC 0.41 ZNF438 Intergenic 0.82 (0.78–0.86) 1.20E–15 0.75 (0.7–0.81) 0.88 (0.81–0.97) 0.86 (0.78–0.94) 0.015 0.76
rs7995158 13 110459370 G A 0.55 COL4A2 (COL4A2-AS2) 3’ UTR (Intronic) 0.82 (0.79–0.86) 1.81E–15 0.83 (0.78–0.89) 0.79 (0.72–0.86) 0.85 (0.78–0.93) 0.47 0
rs39375 7 103837624 C A 0.41 RELN Intronic 1.21 (1.15–1.27) 3.21E–14 1.27 (1.18–1.37) 1.14 (1.04–1.25) 1.18 (1.08–1.29) 0.15 0.47
rs791903 6 33734868 C G 0.5 IP6K3 Intronic 0.83 (0.8–0.88) 1.15E–13 0.84 (0.79–0.91) 0.82 (0.75–0.89) 0.84 (0.76–0.92) 0.85 0
rs753138805 4 87845066 G GGAAA 0.0033 MEPE Frameshift 9.80E–14 21.5 (9.6–48.4) NA NA NA NA
rs181831514 4 87901594 T C 0.0024 MEPE Intergenic 12.3 (6.09–24.9) 2.87E–12 19.66 (8.92–43.33) NA 2.04 (0.43–9.62) 0.011 0.85
rs4917 3 186619924 C T 0.64 AHSG Missense 0.84 (0.8–0.88) 3.35E–12 0.86 (0.8–0.92) 0.77 (0.7–0.85) 0.88 (0.8–0.97) 0.12 0.52
rs13192457 6 44887654 A C 0.44 SUPT3H Intronic 1.21 (1.14–1.28) 4.80E–11 1.3 (1.21–1.39) 1.07 (0.98–1.18) NA 0.0013 0.9
rs4636903 16 54995451 T C 0.12 IRX5 Intergenic 1.28 (1.19–1.39) 7.32E–11 1.35 (1.2–1.52) 1.36 (1.18–1.56) 1.14 (0.99–1.31) 0.12 0.52
rs67284550 16 1480948 T C 0.42 PTX4 Downstream gene 1.17 (1.12–1.23) 1.43E–10 1.25 (1.16–1.34) 1.13 (1.03–1.24) 1.09 (1–1.2) 0.055 0.66
rs11683921 2 111714056 G T 0.38 ANAPC1 Intronic 1.17 (1.11–1.23) 3.23E–10 1.21 (1.12–1.3) 1.13 (1.03–1.24) 1.15 (1.05–1.27) 0.49 0
rs553652 11 96200151 A G 0.92 MAML2 Intronic 1.3 (1.2–1.42) 9.24E–10 1.35 (1.2–1.52) 1.31 (1.08–1.6) 1.21 (1.04–1.42) 0.55 0
rs73172296 13 42525753 A G 0.11 TNFSF11 Intergenic 1.26 (1.17–1.36) 1.18E–09 1.25 (1.13–1.4) 1.42 (1.2–1.68) 1.19 (1.03–1.36) 0.27 0.23
rs485107 8 8723898 G C 0.53 CLDN23 Intergenic 1.16 (1.1–1.21) 2.20E–09 1.17 (1.09–1.26) 1.15 (1.05–1.26) 1.14 (1.04–1.25) 0.92 0
rs2762049 13 50248227 C G 0.39 KCNRG (DLEU1) Intergenic (Intronic) 1.16 (1.1–1.22) 2.34E–09 1.19 (1.11–1.28) 1.12 (1.02–1.23) 1.15 (1.05–1.26) 0.58 0
rs4877080 9 89398813 A T 0.28 SEMA4D Intronic 0.83 (0.78–0.88) 3.60E–09 0.84 (0.78–0.91) 0.81 (0.73–0.89) NA 0.52 0
rs201694067 1 219593023 T TGA 0.33 ZC3H11B Intergenic 1.19 (1.12–1.26) 4.30E–09 1.18 (1.09–1.27) NA 1.22 (1.11–1.34) 0.54 0
rs6066825 20 48723580 G A 0.32 PREX1 Intronic 1.16 (1.1–1.22) 1.20E–08 1.17 (1.08–1.27) 1.25 (1.14–1.37) 1.06 (0.96–1.17) 0.066 0.63
rs66487118 19 10142669 A G 0.3 DNMT1 Intronic 1.16 (1.1–1.23) 1.76E–08 1.14 (1.05–1.24) 1.26 (1.15–1.39) 1.1 (0.99–1.21) 0.12 0.53
rs8105161 19 41333726 C T 0.16 TGFB1 Intronic 0.83 (0.78–0.89) 2.71E–08 0.81 (0.74–0.89) 0.85 (0.75–0.97) 0.86 (0.76–0.96) 0.71 0
rs2118612 15 67108152 T C 0.79 SMAD3 Intronic 0.85 (0.8–0.9) 3.34E–08 0.84 (0.77–0.92) 0.81 (0.73–0.91) 0.89 (0.79–0.99) 0.59 0
rs4464751 6 73707844 T G 0.54 CD109 Intronic 1.14 (1.09–1.2) 3.58E–08 1.15 (1.07–1.24) 1.18 (1.07–1.29) 1.1 (1.01–1.2) 0.58 0
rs80339979 9 99889430 G GA 0.64 STX17 (STX17-AS1) Intergenic (Intronic) 1.15 (1.09–1.21) 3.66E–08 1.1 (1.03–1.19) 1.16 (1.05–1.27) 1.22 (1.11–1.34) 0.26 0.27
rs6066131 20 46941020 C T 0.45 EYA2 Intronic 1.14 (1.09–1.2) 4.91E–08 1.17 (1.09–1.26) 1.13 (1.03–1.24) 1.11 (1.01–1.21) 0.57 0

A total of 3,504 cases and 861,198 controls from FinnGen, Estonian Biobank and UK Biobank were included in the meta-analysis. A Bonferroni-corrected two-sided genome-wide p-value threshold of 5×10−8 was used to establish significance, accounting for multiple comparisons. For all loci, the nearest protein-coding gene is shown. RNA and antisense genes overlapping the lead variant are additionally shown in parentheses. In addition to the 27 lead variants from the meta-analysis, data (in italic) are presented for the frameshift variant rs753138805 in MEPE which was observed only in FinnGen and was not included in the meta-analysis. The p-value for Cochran’s Q test and the I2 statistic are reported for each lead variant. Chr chromosome, EA effect allele, EAF effect allele frequency, NEA non-effect allele, OR odds ratio, CI confidence interval.